Hastings; Michelle L.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Hastings; Michelle L..The latest application filed is for "compounds and methods for modulating cln3 expression".

Company Profile

4.13.20

Hastings; Michelle L. - North Chicago IL
Hastings; Michelle L - Lake Bluff IL
HASTINGS; Michelle L. - Lake Bluff IL

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Compounds And Methods For Modulating Cln3 Expression App 20220280545 - Hastings; Michelle L. ; et al.	2022-09-08
Antisense Compounds Targeting Genes Associated with Cystic Fibrosis App 20220054526 - Hastings; Michelle L.	2022-02-24
Antisense Compounds Targeting Genes Associated with Cystic Fibrosis App 20210401869 - Hastings; Michelle L. ; et al.	2021-12-30
Antisense compounds targeting genes associated with cystic fibrosis Grant 11,116,785 - Hastings September 14, 2	2021-09-14
Antisense compounds targeting Leucine-Rich repeat kinase 2(LRRK2) for the treatment of Parkinsons disease Grant 10,787,669 - Hastings , et al. September 29, 2	2020-09-29
Antisense Compounds and Uses Thereof App 20200216846 - Rigo; Frank ; et al.	2020-07-09
Antisense Compounds Targeting Genes Associated With Cystic Fibrosis App 20200129539 - Hastings; Michelle L.	2020-04-30
Antisense compounds targeting genes associated with cystic fibrosis Grant 10,544,417 - Hastings Ja	2020-01-28
Antisense compounds targeting genes associated with cystic fibrosis Grant 10,525,076 - Hastings J	2020-01-07
Antisense compounds targeting apolipoprotein E receptor 2 Grant 10,472,634 - Rigo , et al. Nov	2019-11-12
Antisense Compounds Targeting Leucine-Rich Repeat Kinase 2(LRRK2) For The Treatment of Parkinsons Disease App 20190309304 - Hastings; Michelle L. ; et al.	2019-10-10
Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons disease Grant 10,370,667 - Hastings , et al.	2019-08-06
Antisense Compounds Targeting Genes Associated With Cystic Fibrosis App 20180119152 - HASTINGS; Michelle L.	2018-05-03
Antisense Compounds Targeting Genes Associated With Cystic Fibrosis App 20180117073 - Hastings; Michelle L.	2018-05-03
Antisense Compounds Targeting Leucine-Rich Repeat Kinase 2 (LRRK2) For The Treatment Of Parkinsons Disease App 20180094266 - HASTINGS; Michelle L. ; et al.	2018-04-05
Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons disease Grant 9,840,710 - Hastings , et al. December 12, 2	2017-12-12
Antisense compounds targeting genes associated with cystic fibrosis Grant 9,840,709 - Hastings December 12, 2	2017-12-12
Antisense Compounds And Uses Thereof App 20170268000 - RIGO; Frank ; et al.	2017-09-21
Antisense Compounds Targeting Apolipoprotein E Receptor 2 App 20170191066 - Rigo; Frank ; et al.	2017-07-06
Antisense Compounds Targeting Leucine-Rich Repeat Kinase 2 (LRRK2) For The Treatment Of Parkinsons Disease App 20170137826 - Hastings; Michelle L. ; et al.	2017-05-18
Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for usher syndrome Grant 9,556,434 - Hastings January 31, 2	2017-01-31
Antisense Compounds Targeting Genes Associated With Cystic Fibrosis App 20160244767 - HASTINGS; Michelle L.	2016-08-25
Antisense compounds targeting genes associated with usher syndrome Grant 9,353,371 - Hastings , et al. May 31, 2	2016-05-31
Antisense Oligonucleotides That Target A Cryptic Splice Site In Ush1c As A Therapeutic For Usher Syndrome App 20150315590 - HASTINGS; Michelle L.	2015-11-05
Antisense Oligonucleotides That Target A Cryptic Splice Site In Ush1c As A Therapeutic For Usher Syndrome App 20140243388 - Hastings; Michelle L.	2014-08-28
Antisense Compounds Targeting Genes Associated With Usher Syndrome App 20140114057 - Hastings; Michelle L. ; et al.	2014-04-24
Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome Grant 8,648,053 - Hastings February 11, 2	2014-02-11
Antisense Oligonucleotides That Target A Cryptic Splice Site In Ush1c As A Therapeutic For Usher Syndrome App 20130035367 - Hastings; Michelle L.	2013-02-07
Antisense Oligonucleotides That Target A Cryptic Splice Site In Ush1c As A Therapeutic For Usher Syndrome App 20120165389 - Hastings; Michelle L.	2012-06-28

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.